Prevention of radiotherapy-induced emesis

Area of Science:

• Oncology
• Radiotherapy
• Pharmacology

Background:

• Radiation-induced emesis is a significant side effect of anticancer radiotherapy, often leading to treatment interruption and reduced quality of life.
• While chemotherapy-induced emesis has extensive literature, research on preventing radiotherapy-induced nausea and vomiting is less comprehensive.
• Metoclopramide and selective 5-HT3 antagonists are used, but their efficacy specifically for radiation-induced emesis requires further evaluation.

Purpose of the Study:

• To review radioprotective compounds and novel combination therapies for preventing radiation-induced emesis.
• To summarize clinical practice guidelines for antiemetic use in anticancer therapy, focusing on radiotherapy.
• To highlight the need for more research on antiemetic efficacy in radiation therapy.

Main Methods:

• Literature review of radioprotective compounds and combination therapies.
• Analysis of existing studies on antiemetic drug efficacy in radiotherapy.
• Summary of recent clinical practice guidelines from the American Society of Clinical Oncology (ASCO).

Main Results:

• Radiation-induced emesis impacts treatment continuity and patient well-being.
• The effectiveness of antiemetic drugs like metoclopramide and 5-HT3 antagonists in radiotherapy needs more specific investigation.
• ASCO guidelines offer a framework for antiemetic use in cancer therapy.

Conclusions:

• Optimizing antiemetic strategies is crucial for maintaining radiotherapy schedules and improving patient outcomes.
• Further research is needed to establish evidence-based protocols for preventing nausea and vomiting in radiation oncology.
• Current guidelines provide a foundation, but tailored approaches for radiation-induced emesis are essential.